Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV

HIV / AIDS

Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors

Clin Infect Dis.

Deutschmann E, Bucher HC, Jaeckel S, Gibbons S, McAllister K, Scherrer AU, Braun DL, Cavassini M, Hachfeld A, Calmy A, Battegay M, Cipriani M, Elzi L, Young J, Lopez-Centeno B, Berenguer J, Khoo S, Moffa G, Marzolini C, Swiss HIV Cohort Study.

doi: 10.1093/cid/ciaa918.

HIV / AIDS

Escitalopram population pharmacokinetics in people living with HIV and in the psychiatric population: drug-drug interactions and probability of target attainment

Br J Clin Pharmacol.

Courlet P, Guidi M, Glatard A, Alves Saldanha S, Cavassini M, Buclin T, Marzolini C, Eap CB, Decosterd LA, Csajka C, Swiss HIV Cohort Study.

doi: 10.1111/bcp.13994.

HIV / AIDS

Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study

AIDS.

Stader F, Decosterd L, Stoeckle M, Cavassini M, Battegay M, Saldanha SA, Marzolini C, Courlet P, and the Swiss HIV Cohort Study

doi: 10.1097/QAD.0000000000002489.

HIV / AIDS

How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?

HIV Med.

Metral M, Nadin I, Locatelli I, Tarr PE, Calmy A, Kovari H, Brugger P, Cusini A, Gutbrod K, Schmid P, Schwind M, Kunze U, Di Benedetto C, Pignatti R, Du Pasquier R, Darling K, Cavassini M, Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study group, Swiss HIV Cohort Study.

doi: 10.1111/hiv.12828.

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

HIV / AIDS

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study

Virus Evol.

Kusejko K, Kadelka C, Marzel A, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD, Swiss HIV Cohort Study

doi: 10.1093/ve/vey024.

Further Publications Anesthesiology

Polypharmacy, potentially inappropriate medication, and pharmacogenomics drug exposure in the Rhineland Study

Br J Clin Pharmacol

de Vries FM, Stingl JC, Breteler MMB

doi: 10.1111/bcp.14671

HIV / AIDS

Do people living with HIV experience greater age advancement than their HIV-negative counterparts?

AIDS.

De Francesco D, Wit FW, Bürkle A, Oehlke S, Kootstra NA, Winston A, Franceschi C, Garagnani P, Pirazzini C, Libert C, Grune T, Weber D, Jansen EHJM, Sabin CA, Reiss P; the Co-morBidity in Relation to AIDS (COBRA) Collaboration

doi: 10.1097/QAD.0000000000002063.

HIV / AIDS

Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017

HIV Med.

Hampel B, Kusejko K, Kouyos RD, Böni J, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Nicca D, Schmidt AJ, Nguyen H, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Braun DL, Fehr J, Swiss HIV Cohort Study group.

doi: 10.1111/hiv.12821.

Related content

Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors

Escitalopram population pharmacokinetics in people living with HIV and in the psychiatric population: drug-drug interactions and probability of target attainment

Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study

How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study

Polypharmacy, potentially inappropriate medication, and pharmacogenomics drug exposure in the Rhineland Study

Do people living with HIV experience greater age advancement than their HIV-negative counterparts?

Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017